“The market is showing less sensitivity to higher bond yields,” Haeling said.
Among individual companies, Johnson & Johnson rose 1.7% after announcing a deal to acquire Intra-Cellular Therapies for about US$14.6 billion ($26.1b).
Intra-Cellular, which focuses on treatments for depression and schizophrenia, jumped 34.1%.
But Moderna sank 16.8% as it projected 2025 revenues of between $1.5 and $2.5b, falling from the 2024 level of around $3b.
Retail shares were mixed following financial updates that included inputs from the critical holiday shopping season. Macy’s dropped 8.2% and Abercrombie & Fitch slumped 15.6% but Lululemon Athletica climbed 0.9%.
This week’s calendar includes earnings from large banks, as well as economic releases on US inflation and retail sales.
© Agence France-Presse